IL2 and neoplasm: Administration of either IL-2/S4B6 or IL-2/JES6 (2 μg IL-2/dose) before ICIs did not affect tumor growth compared with ICIs alone (figure 3F) and led to slightly worse (though not statistically significantly) survival (figure 3G).